Sort
21,281 grants matching “influenza”
Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment
$949,201Hilliard Kutscher · Pop Biotechnologies, Inc · R44 · FY2025 · AI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
$948,264Harold A Chapman · University Of California, San Francisco · U01 · FY2017 · HL
Fc effector function in bNAbs
$947,985Jeffrey Victor Ravetch · California Institute Of Technology · P01 · FY2014 · AI
Development of highly potent human monoclonal for RSV immuno-prophylaxis
$947,868Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2022 · AI
Identification and Development of Anti-Flavivirus Lead Drug Candidates
$947,621Jay A Nelson · University Of Alabama At Birmingham · U19 · FY2017 · AI
Rapid Estimation of Influenza Vaccine Effectiveness in a Wisconsin Population Coh
$946,209Edward Belongia · Marshfield Clinic Research Foundation · U18 · FY2010 · IP
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
$945,791Arnab Basu · Microbiotix, Inc · R44 · FY2014 · AI
Characterization of virus-specific human B cell subsets in lymphoid and non-lymphoid tissues
$945,780Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2023 · AI
Collectins and Innate Defense against Inhaled Pathogens
$945,582Barbara A Seaton · Boston University Medical Campus · P01 · FY2009 · AI
Identification and characterization of novel drugs that target the Influenza
$945,389Richard J. Whitley · University Of Alabama At Birmingham · U19 · FY2018 · AI
Modeling, Spatial, Statistics
$945,379Ira M Longini · Fred Hutchinson Cancer Research Center · U54 · FY2015 · GM
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness
$945,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2014 · IP
Core_Prospective population-based estimation of influenza vaccine effectiveness a
$944,982Michael L Jackson · Kaiser Foundation Health Plan Of Washington · U01 · FY2014 · IP
NSF Convergence Accelerator - Track D: Data-Driven Disease Control and Prevention in Veterinary Health
$944,875Beatriz Martinez Lopez · University Of California-Davis · · FY2020 · TIP
Therapeutics for drug-resistant bacteria: arylmyxopyronins
$944,067Richard H. Ebright · Hackensack University Medical Center · U19 · FY2025 · AI
Develop, Optimize and Commercialize UltraMarathonRT: A new enzyme for unbiased transcriptomic and epitranscriptomic characterization of RNAs regardless of length or composition.
$944,054Li-Tao Guo · Rnaconnect Inc · R44 · FY2025 · GM
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.
$943,229Iain James Macleod · Aldatu Biosciences, Inc. · R44 · FY2024 · AI
Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases
$942,068Kai W Wucherpfennig · Dana-Farber Cancer Inst · P01 · FY2009 · AI
Systems Biology Analysis of Influenza A Virus and Ebola Virus
$941,909Yoshihiro Kawaoka · University Of Wisconsin-Madison · U19 · FY2013 · AI
Strain-Independent Therapeutic Antibodies for Influenza
$941,551Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2015 · AI
Prospective Multicenter Study of Bronchiolitis Admissions: Etiology & Disposition
$941,304Carlos A. Camargo · Massachusetts General Hospital · U01 · FY2009 · AI
Analysis and Modulation of Virus-Host Interaction in Infections of the Liver
$940,899Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK
Cellular Immunity and Memory to SARS-CoV-2
$940,081Elizabeth B Norton · Tulane University Of Louisiana · U54 · FY2020 · CA
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
$939,591Mark Yondola · Calder Biosciences, Inc. · R44 · FY2020 · AG
Plasma Gelsolin as Immunotherapeutic for Antibiotic-Resistant Pneumonia
$939,359Lester Kobzik · Harvard School Of Public Health · R01 · FY2016 · AI